Morgan Stanley Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $13.00

Elanco Animal Health (NYSE:ELAN - Free Report) had its target price trimmed by Morgan Stanley from $14.00 to $13.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

Several other brokerages have also weighed in on ELAN. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. UBS Group began coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a "buy" rating and a $18.00 price target on the stock. Finally, Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $15.83.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded up $0.11 during trading hours on Wednesday, reaching $11.03. 2,004,298 shares of the stock were exchanged, compared to its average volume of 4,831,348. The stock has a 50 day moving average of $11.72 and a two-hundred day moving average of $13.05. The company has a market cap of $5.45 billion, a P/E ratio of 27.54, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a twelve month low of $10.20 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the firm earned $0.08 earnings per share. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. Equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors have recently bought and sold shares of ELAN. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at $29,000. AM Squared Ltd purchased a new stake in Elanco Animal Health during the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB bought a new position in Elanco Animal Health during the third quarter worth about $35,000. Farther Finance Advisors LLC raised its holdings in Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock valued at $49,000 after acquiring an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock worth $50,000 after acquiring an additional 1,601 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.